BSECompany UpdateMgmt Change24 Jul 2026
Fabtech Technologies Ltd
Change in Directors
Fabtech Technologies Ltd announced a change in directors, with Mr. Naushad Alimohmed Panjwani re-appointed as a Non-Executive Independent Director and Chairperson of the Company. The Board also approved the notice convening the 8th Annual General Meeting, scheduled to be held on August 24, 2026, and fixed August 17, 2026, as the Record Date for determining the entitlement of members to receive the final dividend.
BSEBoard MeetingResults24 Jul 2026
Fabtech Technologies Ltd
Outcome of Board Meeting
Fabtech Technologies Ltd announced the outcome of its board meeting, approving un-audited financial results for the quarter ended June 30, 2026, and re-appointment of a non-executive director. The board also fixed a record date for a final dividend and convened the 8th Annual General Meeting.
BSECompany UpdateResults23 Jul 2026
Fabtech Technologies Ltd
Intimation about Earnings Conference Call shceduled to discuss the Unaudited Financial Results for the quarter and three months ended June 30, 2026
Fabtech Technologies Ltd has scheduled an Earnings Conference Call to discuss the Unaudited Financial Results for the quarter and three months ended June 30, 2026.
BSEBoard MeetingResults21 Jul 2026
Fabtech Technologies Ltd
Fabtech Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/07/2026 ,inter alia, to consider and approve un-audited Standalone ....
Fabtech Technologies Ltd has scheduled a Board meeting on July 24, 2026, to consider and approve the un-audited standalone and consolidated financial results for the first quarter ended June 30, 2026.
BSECompany Update▲ PositiveResults23 Jun 2026
Fabtech Technologies Ltd
Intimation of Investor Presentation
Fabtech Technologies Ltd. presented its FY26 investor update, reporting a resilient year with strong financial performance. Standalone revenue grew 25.7% YoY to ₹410.77 Cr, and operational profit increased 17.0% YoY to ₹36.60 Cr. The company secured a consolidated order book of over ₹900 Cr as of March 31, 2026, providing significant revenue visibility. Strategic expansions include entry into Animal Health, KSA vaccine and pharma projects, large Africa pharma wins, and a European acquisition, positioning it as a global life sciences infrastructure platform.